Quantcast

Latest TB Alliance Stories

2014-07-31 08:37:14

Brock Will Lead Resource Development, Advocacy, Community Engagement Efforts in Support of Promising Research Pipeline NEW YORK, July 31, 2014 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit with the mission of discovering and developing better, faster and affordable treatments, announced the appointment of Willo Brock as Senior Vice President, External Affairs. Mr. Brock comes to TB Alliance having most recently served as Head of Major Donor Relations for WWF...

2014-07-31 08:37:08

Robertson Will Lead Initiatives to Accelerate Adoption of New TB Drug Regimens NEW YORK, July 31, 2014 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing better, faster and affordable treatments for tuberculosis (TB), announced the appointment of Elana Robertson to Senior Vice President, Market Access. Ms. Robertson joins the organization from Novartis Vaccines, where she was responsible for the company's business in Sub-Saharan...

2014-05-14 08:32:24

Fotouhi to guide organization's discovery-stage research and clinical trials of drug candidates NEW YORK, May 14, 2014 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization dedicated to developing better, faster, and affordable treatments for tuberculosis (TB), announced the appointment of Nader Fotouhi, Ph.D. as Chief Scientific Officer. Nader comes to the TB Alliance with nearly 25 years of experience, having served most recently as Vice President & Global Head...

2014-04-23 16:29:42

Partnership Supports Newly Announced STAND Trial SEATTLE, April 23, 2014 /PRNewswire-USNewswire/ -- TB Alliance, an international non-profit drug development organization that develops better, faster-acting, and affordable tuberculosis (TB) drugs, has announced that it is collaborating with, and has granted an exclusive license to, the Shanghai Fosun Pharmaceutical Development Co., Ltd., and its subsidiary Shenyang Hongqi Pharmaceutical Co., Ltd. (Fosun Pharma), to develop and...

2014-04-23 16:29:39

STAND trial will test the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB SEATTLE, April 23, 2014 /PRNewswire-USNewswire/ -- Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multi-drug resistant tuberculosis (TB) to a global Phase 3 clinical trial. The announcement by Bill Gates, co-chair of the Bill...

2014-02-04 12:27:12

Multi-year grant brings together non-profits, government, academia and the pharmaceutical industry to study pressing public health challenge TUCSON, Ariz., Feb. 4, 2014 /PRNewswire-USNewswire/ -- The Critical Path Institute, an independent, non-profit that catalyzes innovative ideas that accelerate the speed of drug and medical product development, today announced it has received a three-year grant from the Bill & Melinda Gates Foundation. The grant will be used to develop...

2014-01-23 11:29:46

A major trial aiming to cut the rate of tuberculosis (TB) among South Africa's gold miners did not reduce the number of cases or deaths from the disease, according to a study published in the New England Journal of Medicine. Researchers from the London School of Hygiene & Tropical Medicine say that the results demonstrate the scale of the TB problem in South African gold mines, and highlight the need for a "combination prevention" approach to improve TB control. The TB epidemic in...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related